Summit Therapeutics Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025: USD -234.81 M

Summit Therapeutics Inc. EBITDA is USD -234.81 M for the Trailing 12 Months (TTM) ending March 31, 2025. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Summit Therapeutics Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -585.20 M, a 545.61% change year over year.
  • Summit Therapeutics Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -90.64 M, a 50.59% change year over year.
  • Summit Therapeutics Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -60.19 M.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)